Compare · AZN vs GYRE
AZN vs GYRE
Side-by-side comparison of AstraZeneca PLC (AZN) and Gyre Therapeutics Inc. (GYRE): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both AZN and GYRE operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- AZN is the larger of the two at $563.07B, about 959.2x GYRE ($587.0M).
- Over the past year, AZN is down 3.5% and GYRE is down 28.9% - AZN leads by 25.4 points.
- AZN has been more active in the news (21 items in the past 4 weeks vs 7 for GYRE).
- AZN has more recent analyst coverage (25 ratings vs 3 for GYRE).
- Company
- AstraZeneca PLC
- Gyre Therapeutics Inc.
- Price
- $181.67-2.33%
- $6.05-4.12%
- Market cap
- $563.07B
- $587.0M
- 1M return
- -0.57%
- -14.37%
- 1Y return
- -3.51%
- -28.91%
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NYSE
- NASDAQ
- IPO
- 2026
- 2006
- News (4w)
- 21
- 7
- Recent ratings
- 25
- 3
AstraZeneca PLC
AstraZeneca PLC discovers, develops, manufactures, and commercializes prescription medicines in the areas of oncology, cardiovascular, renal and metabolism, respiratory, infection, neuroscience, and gastroenterology worldwide. The company's marketed products include Tagrisso, Lynparza, Imfinzi, Enhertu, Koselugo, Lumoxiti, Equidacent, Zoladex, Faslodex, Iressa, Arimidex, Casodex/Cosudex, and others for oncology diseases; Onglyza, Bydureon, Lokelma, Byetta, Qtern, Symlin, and others for cardiovascular, renal, and metabolism diseases; and Symbicort, Pulmicort, Fasenra, Daliresp/Daxas, Duaklir, Tudorza/Eklira, Bevespi, Breztri, Anifrolumab, and others for respiratory and immunology diseases. It also offers other medicines and COVID-19 products, including Synagis, Fluenz Tetra/FluMist Quadrivalent, Seroquel IR/Seroquel XR, Vimovo, Movantik/Moventig, Nexium, Losec/Prilosec, and COVID-19 Vaccine AstraZeneca. The company serves primary care and specialty care physicians through distributors and local representative offices. It has a collaboration agreement with Daiichi Sankyo to develop and commercialize DS-1062 for the treatment of trophoblast cell-surface antigen 2 (TROP2) tumor; AliveCor, Inc. to develop non-invasive potassium monitoring solutions; Massachusetts General Hospital to accelerate digital health solutions; Sanguina on smartphone application study for hemoglobin management in patients with anemia of chronic kidney disease; Alchemab to enhance prostate cancer research; and Proteros biostructures GmbH to discover and develop novel small molecules for the treatment of various types of cancer. The company was formerly known as Zeneca Group PLC and changed its name to AstraZeneca PLC in April 1999. It has a collaboration agreement with Regeneron Pharmaceuticals, Inc. to research, develop, and commercialize small molecule medicines for obesity. AstraZeneca PLC was incorporated in 1992 and is headquartered in Cambridge, the United Kingdom.
Latest AZN
- NYSE Content Update: AstraZeneca Celebrates Largest Transfer in NYSE History
- Camizestrant Combination Delayed Time to First Progression by 55% and to Second Progression by 37% in Patients With Advanced HR-positive Breast Cancer With an Emergent ESR1 Tumor Mutation in SERENA-6 Trial
- SEC Form 6-K filed by AstraZeneca PLC
- SEC Form 6-K filed by AstraZeneca PLC
- IMFINZI® (durvalumab) plus IMJUDO® (tremelimumab-actl) combined with lenvatinib and TACE reduced the risk of disease progression or death by 30% in embolization-eligible unresectable liver cancer in EMERALD-3 Phase III trial
- SEC Form 6-K filed by AstraZeneca PLC
- IMFINZI® (durvalumab) approved in the US in first and only immunotherapy combination for patients with BCG-naïve, high-risk non-muscle-invasive bladder cancer
- SEC Form 25-NSE filed by AstraZeneca PLC
- SEC Form 6-K filed by AstraZeneca PLC
- SEC Form 6-K filed by AstraZeneca PLC
Latest GYRE
- Chief Operating Officer Ye Weiguo exercised 34,976 shares at a strike of $0.75 and sold $218,561 worth of shares (34,976 units at $6.25) (SEC Form 4)
- Gyre Therapeutics Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits
- Chief Operating Officer Ye Weiguo exercised 7,500 shares at a strike of $0.75 and sold $45,680 worth of shares (7,500 units at $6.09) (SEC Form 4)
- Chief Operating Officer Ye Weiguo exercised 22,220 shares at a strike of $0.75 and sold $136,653 worth of shares (22,220 units at $6.15) (SEC Form 4)
- SEC Form 4 filed by Director Zhang Ping
- Chief Operating Officer Ye Weiguo exercised 9,320 shares at a strike of $0.75 and sold $59,418 worth of shares (9,320 units at $6.38) (SEC Form 4)
- Chief Operating Officer Ye Weiguo exercised 28,680 shares at a strike of $0.75 and sold $194,773 worth of shares (28,680 units at $6.79) (SEC Form 4)
- Gyre Therapeutics Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits
- Gyre Therapeutics Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits
- Gyre Therapeutics Announces NMPA Acceptance of New Drug Application for F351 (hydronidone) for CHB-Induced Liver Fibrosis Treatment